Investment in Possible Future Generic Marketing Excludes Legitimate Basis for Pharma Settlement, Suggests EU Advocate General

Published date09 June 2020
Subject MatterCompetition,Marketing,Patents,Manufacturers,Pay-For-Delay,EU,Cartels,Generic Drugs,Advocate General,Intellectual Property Protection,European Court of Justice (ECJ),Pharmaceutical Industry
AuthorIngrid Vandenborre,Frederic Depoortere,Giorgio Motta,Michael Frese,Thorsten Goetz,Bill Batchelor
Law FirmSkadden, Arps, Slate, Meagher & Flom LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT